Table 3.

FLEX Baseline Bone Mineral Density (BMD), Bone Turnover Markers (BTMs), and Other Characteristics and Age- Adjusted Risk of Fracture Among Women Who Discontinued Alendronate Therapy

Variables Measured at FLEX Baseline^a	Risk of Fracture, Relative Hazard Ratio (95% CI)^b
Demographic and clinical characteristics
Age, per 5-y increase, y	1.54 (1.26–1.85)^c
BMI, per SD increase	1.10 (0.87–1.38)
Vertebral fracture	1.11 (0.71–1.75)
Previous nonspine fracture	1.24 (0.64–2.40)
BMD, lowest tertile vs other 2, T score
Total hip	1.87 (1.20–2.92)^c
Femoral neck	2.17 (1.38–3.41)^c
BTMs, highest tertile vs other 2
NTX/Cr, nmol/mmol	1.33 (0.84–2.10)
BAP, ng/mL	1.39 (0.89–2.17)

Abbreviations: BAP, bone-specific alkaline phosphatase; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); FLEX, Fracture Intervention Trial Long-term Extension; NTX/Cr, type 1 collagen cross-linked N-telopeptide to creatinine concentration ratio.

With the exception of age, each variable was examined in a separate age-adjusted model.

Any nonspine or clinical vertebral fracture occurring after the 1-year visit.

Statistically significant association.